Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

Artificial intelligence is changing the way industries do business. But executives in the pharmaceutical industry are still ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...

Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold ...

It's been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company's financial results dipped following ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Shares of Bristol Myers Squibb Co. BMY dropped 0.08% to $59.22 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.56% to ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.27 which represents a slight increase of $0.53 or 0.90% from the prior close of $58.74. The stock opened at ...